While CDK4/6 inhibitors have most evidence for treatment of LPS, a recent phase II study evaluated palbociclib for treatment of other types of STS and osteosarcoma with have high CDK4 expression and underexpressed CDKN2A mRNA (80). This evidence concerns the gene CDK4 and telomere syndrome.